Safety considerations of recombinant protein therapy: Introductory comments

被引：2

作者：

Hayes, TJ ^{[1
]}

Ryffel, B ^{[1
]}

机构：

[1] INST PATHOL,CH-4031 BASEL,SWITZERLAND

来源：

CLINICAL IMMUNOLOGY AND IMMUNOPATHOLOGY | 1997年 / 83卷 / 01期

关键词：

D O I：

10.1006/clin.1996.4301

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

引用

页码：1 / 4

页数：4

共 11 条

[1]

Aggarwal B.B., 1995, HUMAN CYTOKINES THEI

[2]

ANDERSON TD, 1993, INT REV EXP PATHOL, V34, P9

[3]

BEUTLER B, 1993, CRIT CARE MED, V21, pS423

[4]

DEXTER TM, 1990, COLONY STIMULATING F

[5] Immunogenicity of recombinant human interleukin-3 [J].

Gunn, H .

CLINICAL IMMUNOLOGY AND IMMUNOPATHOLOGY, 1997, 83 (01) :5-7

[6] PROGRESS AND CHALLENGES IN THE PRECLINICAL ASSESSMENT OF CYTOKINES [J].

HAYES, TJ ;

CAVAGNARO, JA .

TOXICOLOGY LETTERS, 1992, 64-5 :291-297

[7] Extrapolation of experimental safety data to humans: The interleukin-6 case [J].

Kammuller, M ;

Ryffel, B .

CLINICAL IMMUNOLOGY AND IMMUNOPATHOLOGY, 1997, 83 (01) :15-17

[8] TOXICOLOGIC EVALUATIONS OF AN IMMUNOTOXIN, H65-RTA [J].

KUNG, AHC ;

CAVAGNARO, JA ;

MAKIN, A ;

WHITE, MA ;

KONG, KN .

FUNDAMENTAL AND APPLIED TOXICOLOGY, 1995, 26 (01) :75-84

[9]

METCALF D, 1995, HEMOPOIETIC COLONIES

[10] Interleukin-12: Role of interferon-gamma in IL-12 adverse effects [J].

Ryffel, B .

CLINICAL IMMUNOLOGY AND IMMUNOPATHOLOGY, 1997, 83 (01) :18-20

← 1 2 →